Can Bone Marrow Dosimetric Parameters Predict for Myelotoxicity in Cervical Cancer Patients Treated With Concurrent Chemotherapy and Extended-Field Intensity-Modulated Pelvic Radiotherapy (EF-IMRT)?

Abstract

Peer reviewed

G.N. Gan, S. Beriwal, D.E. Heron, H. Kim and R. Lalonde

International journal of radiation oncology, biology, physics, v 69(3), pp S395-S396

01 Nov 2007

Additional Links

4 Record Views

Title: Can Bone Marrow Dosimetric Parameters Predict for Myelotoxicity in Cervical Cancer Patients Treated With Concurrent Chemotherapy and Extended-Field Intensity-Modulated Pelvic Radiotherapy (EF-IMRT)?
Creators: G.N. Gan - UPMC Hillman Cancer Center
S. Beriwal - UPMC Hillman Cancer Center
D.E. Heron - UPMC Hillman Cancer Center
H. Kim - UPMC Hillman Cancer Center
R. Lalonde - UPMC Hillman Cancer Center
Publication Details: International journal of radiation oncology, biology, physics, v 69(3), pp S395-S396
Publisher: ELSEVIER SCIENCE INC; NEW YORK
Number of pages: 2
Resource Type: Abstract
Language: English
Academic Unit: Radiation Oncology (and Nuclear Medicine)
Web of Science ID: WOS:000249950201033
Other Identifier: 991021897390604721

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas: Oncology; Radiology, Nuclear Medicine & Medical Imaging